Avantor (AVTR) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Revvity (RVTY) has outperformed Avantor (AVTR) over the past year, gaining 68.4% versus a gain of 14.0%. Over five years, RVTY leads with a -9.6% price change compared with -60.0% for AVTR. Revvity is the larger company by market cap ($16.46 billion vs $10.28 billion), about 1.6 times the size.
On valuation, Avantor trades at a lower forward P/E (17.3x vs 25.0x for Revvity). Revvity pays a dividend yielding 0.19%, while Avantor does not currently pay one. Revvity converts more of its revenue into profit, with a net margin of 8.4% versus -8.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTR | RVTY |
|---|---|---|
| Share price | $15.20 | $147.47 |
| Market cap | $10.28B | $16.46B |
| 1-day change | -0.98% | -3.95% |
| YTD return | +33.94% | +58.76% |
| 1-year return | +13.96% | +68.44% |
| 5-year return | -59.97% | -9.55% |
| P/E ratio (TTM) | — | 70.56 |
| Forward P/E | 17.33 | 25.02 |
| EPS (TTM) | $-0.84 | $2.09 |
| Dividend yield | 0.00% | 0.19% |
| Annual dividend | $0.00 | $0.28 |
| Revenue (latest FY) | $6.55B | $2.86B |
| Revenue growth (YoY) | -3.41% | +3.67% |
| Net income (latest FY) | $-530.20M | $241.20M |
| Gross margin | 32.65% | — |
| Operating margin | -3.76% | 12.49% |
| Net margin | -8.09% | 8.45% |
| 52-week high | $16.38 | $166.25 |
| 52-week low | $7.27 | $81.22 |
| Distance from 52-week high | -7.18% | -11.30% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -2.76% | -7.87% |
| Average volume | 9.43M | 1.79M |
| Shares outstanding | 676.36M | 111.59M |
| Employees | 13,500 | 11,000 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVTY has outperformed AVTR by 54.5 percentage points over the past year.
- Revvity is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -8.1 cents for Avantor.
- Revvity grew revenue faster in its latest fiscal year (+3.67% vs -3.41%).
About Avantor
AVTR stock →Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
AVTR vs RVTY FAQ
Which is bigger, Avantor or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $16.46B compared with $10.28B for Avantor (AVTR).
Which stock has performed better over the past year, AVTR or RVTY?
RVTY returned +68.44% over the past 12 months, compared with +13.96% for AVTR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Avantor or Revvity?
Revvity pays a dividend yielding 0.19%, while Avantor does not currently pay a regular dividend.
Are Avantor and Revvity in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.